Communiqués Alterity Therapeutics Limited OTC Markets

Actions

PRNAF

AU0000043945

Recherche biotechnologique et médicale

Temps Différé OTC Markets Autres places de cotation 17:50:46 01/04/2026			Varia. 5j.	Varia. 1 janv.
0,0550 ^USD	+450,00%		-.--%	-82,40%

09/06	Alterity Therapeutics s'accorde avec la FDA sur le programme pivot de phase 3 pour l'ATH434 dans l'atrophie multisystématisée	CI
19/05	Alterity Therapeutics : les données présentées soutiennent le passage en phase 3 pour son candidat contre l'atrophie multisystématisée	MT

Communiqués

19/05	Alterity Therapeutics : Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy	PU
11/05	Alterity Therapeutics : Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy	PU
07/05	Alterity Therapeutics : to Deliver Presentations at Multiple Medical Conferences in May 2026	PU
10/11	Alterity Therapeutics : Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSAat the 36th International Symposium on the Autonomic Nervous System	PU
02/11	Alterity Therapeutics : Appendix 4C – Q1 FY26 Quarterly Cash Flow Report	PU
09/10/25	Alterity Therapeutics : Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders	PU
02/10/25	Alterity Therapeutics : to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders	PU
15/09/25	Alterity Therapeutics : Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting	PU
08/09/25	Alterity Therapeutics : Raises A$20.0 million in Strategic Placement	PU
02/09/25	Alterity Therapeutics : XBRL 30 June 2025 filed with the SEC	PU
30/07/25	Alterity Therapeutics : Appendix 4C – Q4 FY25 Quarterly Cash Flow Report	PU
28/07/25	Alterity Therapeutics : Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy	PU
23/06/25	Alterity Therapeutics : to Provide Corporate Update in Fireside Chat	PU
12/05/25	Alterity Therapeutics : Prominently Featured at the International MSA Congress	PU
07/05/25	Alterity Therapeutics : Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress	PU
05/05/25	Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy	AQ
30/04/25	Alterity Therapeutics : Appendix 4C – Q3 FY25 Quarterly Cash Flow Report	PU
28/04/25	Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium	AQ
10/04/25	Alterity Therapeutics : Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting	PU
03/04/25	Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting	AQ
27/03/25	Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy	AQ
27/03/25	Alterity Therapeutics : Completes Last Patient Visit in ATH434 202 Open Label Phase 2 Trial in Multiple System Atrophy	PU
10/02/25	Alterity Therapeutics : Raises A$40.0 million in Placement	PU
03/02/25	Alterity Therapeutics : Announces Funding to Accelerate ATH434 Clinical and Business Development Activities	PU
29/01/25	Alterity Therapeutics : Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy	PU